I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant lasofoxifene in molecularly selected patients with hormone receptor positive (HR+)/HE

Wei M, Elias AD, Giridhar K, et al. ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.